Sarah Cannon Research Institute And Bristol Myers Squibb Expand Partnership To Accelerate Cancer Research And Improve Trial Access; Drives 45% Faster Trial

Sarah Cannon Research Institute (SCRI), a global leader in oncology research and community-based clinical trials, has announced an expanded strategic collaboration with Bristol Myers Squibb (NYSE: BMY). The partnership aims to accelerate the development of novel cancer therapies and expand access to clinical trials for patients across the United States. By combining Bristol Myers Squibb’s robust oncology pipeline with SCRI’s nationwide research infrastructure, the initiative seeks to bring advanced cancer research closer to where patients live and receive care.

“At Bristol Myers Squibb, we recognize that accelerating clinical trial enrollment requires not only scientific innovation but also operational innovation. This includes a deep commitment to equity and inclusion, while we look to accelerate overall patient enrollment,” said Mokash Sharma, Senior Vice President, Global Development Operations, Bristol Myers Squibb. “Improving access to clinical research isn’t just about science, it’s about trust, and meeting people where they are. By leveraging data-driven strategies through our collaboration with Sarah Cannon Research Institute, we’re working to ensure that more patients—especially those from medically underserved populations, have access to vital cancer research advances in their communities. This partnership reflects our shared vision to transform clinical trial delivery and advance health equity across the oncology landscape.”

At the core of this collaboration lies SCRI’s Accelero, a next-generation clinical trial delivery platform designed to streamline study operations and shorten trial timelines. With a network of over 200 research locations and more than 1,300 participating physicians across 20 states, SCRI offers a unique community-based model that integrates cutting-edge cancer research into local healthcare settings. This model ensures that patients, regardless of geography, gain access to promising investigational therapies and participate in studies without having to travel to major academic centers.

“Together, SCRI and Bristol Myers Squibb are translating innovative science into clinical trials and accelerating patient enrollment through SCRI’s Accelero model that prioritizes speed, quality, and access, and ultimately brings promising therapies to patients faster and closer to home,” said Dee Anna Smith, Chief Executive Officer, SCRI. “We look forward to the impact we will have together as we reach more patients and continue to redefine how clinical trials are delivered across the country.”

In the initial phase of their partnership, SCRI achieved a 45% reduction in study startup timelines across eight Bristol Myers Squibb clinical trials, significantly outperforming traditional research site benchmarks. The expansion of this collaboration is expected to scale these efficiencies across SCRI’s entire network, reinforcing both organizations’ shared mission to transform clinical trial delivery, improve patient access, and accelerate the advancement of innovative cancer treatments nationwide.